MONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy

M. Toi; C. Huang; Y-H Im; H. Iwata; J.H. Sohn; H-C Wang; N. Masuda; Y. Lin; S. Sakaguchi; N. Bourayou; A. Llombart; G. Sledge

Journal ArticleOPEN ACCESS

MONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy

Toi M
Huang C
Im Y
et al.

Annals of Oncology (2017) 28 x28

DOI: 10.1093/annonc/mdx654.004

N/ACitations

30Readers

Abstract

Background: MONARCH 2 demonstrated that the addition of abemaciclib, a CDK4 &6 inhibitor dosed on a continuous schedule, to fulvestrant (F) significantly improved progression-free survival (PFS) and objective response rate (ORR) compared to placebo (P) plus F (PFS hazard ratio [HR], 0.553, P

Cite

CITATION STYLE

APA

Toi, M., Huang, C., Im, Y.-H., Iwata, H., Sohn, J. H., Wang, H.-C., … Sledge, G. (2017). MONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy. Annals of Oncology, 28, x28. https://doi.org/10.1093/annonc/mdx654.004

MONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy

Abstract

Cite

Register to see more suggestions